Goïta Aïssata Aimée, Guenot Dominique
INSERM U1113/Unistra, IRFAC-Interface de Recherche Fondamentale et Appliquée en Cancérologie, 67200 Strasbourg, France.
Cancers (Basel). 2022 Apr 2;14(7):1810. doi: 10.3390/cancers14071810.
Colorectal cancer is one of the most common cancers, and diagnosis at late metastatic stages is the main cause of death related to this cancer. This progression to metastasis is complex and involves different molecules such as the chemokine CXCL12 and its two receptors CXCR4 and CXCR7. The high expression of receptors in CRC is often associated with a poor prognosis and aggressiveness of the tumor. The interaction of CXCL12 and its receptors activates signaling pathways that induce chemotaxis, proliferation, migration, and cell invasion. To this end, receptor inhibitors were developed, and their use in preclinical and clinical studies is ongoing. This review provides an overview of studies involving CXCR4 and CXCR7 in CRC with an update on their targeting in anti-cancer therapies.
结直肠癌是最常见的癌症之一，晚期转移阶段的诊断是与这种癌症相关的主要死亡原因。这种向转移的进展很复杂，涉及不同的分子，如趋化因子CXCL12及其两种受体CXCR4和CXCR7。这些受体在结直肠癌中的高表达通常与肿瘤的预后不良和侵袭性相关。CXCL12与其受体的相互作用激活了诱导趋化、增殖、迁移和细胞侵袭的信号通路。为此，人们开发了受体抑制剂，并且它们在临床前和临床研究中的应用正在进行中。本综述概述了涉及CXCR4和CXCR7在结直肠癌中的研究，并更新了它们在抗癌治疗中的靶向情况。
